Comirnaty for 6 months to 4 years old (monovalent, Original)

(Note 2)Initial Approval

Coronavirus Modified Uridine RNA Vaccine (SARS-CoV-2) (active ingredient: tozinameran)

Approval Information

Brand NameComirnaty for 6 months to 4 years old (monovalent, Original)

Generic NameCoronavirus Modified Uridine RNA Vaccine (SARS-CoV-2) (active ingredient: tozinameran)

ApprovedOctober 2022

Type(Note 2)Initial Approval

Review Reports

English Review Report

PDF · 652.23 KB

Japanese Review Report

PDF · 1.17 MB

Want structured data, translation summaries & alerts?

PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.

Join the Waitlist

Source: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.

← Back to Drug Database